- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01382199
Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
June 23, 2011 updated by: Ventria Bioscience
A Phase III Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
The purpose of the study is to Evaluate the Efficacy and Safety of Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
340
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
All patients must meet all of the inclusion criteria listed below at the time of enrollment.
- Male and female patients 50 years of age and older.
- Resident of a participating long term care facility.
- Able to consume 30 mL of liquid solution two time per day by mouth or enteral feeding tube.
- Patient has had no antibiotics in the 4 weeks preceding enrollment in the study.
- Patient has been started on a broad spectrum antibiotic(s) for an infection other than gastroenteritis.
- Patient has a life expectancy greater than 6 months.
- Patient or health care agent is able and willing to sign a written informed consent.
- Patient or caregiver is able and willing to complete diary of daily bowel movement information (number, formed or unformed, time) during any portion of the 8 week study.
Exclusion Criteria:
- Patient has an ileostomy.
- Patient has a prior history of major gastrointestinal surgery such as partial small bowel or colon resection or gastric bypass.
- Patient has a history of inflammatory bowel disease.
- Patient has a history of chronic diarrhea associated with irritable bowel syndrome or other etiologies.
- Patient has a history of severe constipation requiring use of enemas or disimpaction within 30 days prior to enrollment.
- Patient has signs or symptoms of C. difficile infection including diarrhea.
- Patient has signs or symptoms of acute or chronic diarrhea.
- Patient has known sensitivity or allergy to rice or rice products.
- Patient has significant medical problems which in the judgment of the principal investigator or medical monitor may interfere with participation in the study.
- Patient is not receiving an antibiotic regimen consisting of a broad spectrum antibiotic.
- Patient has participated in an investigational study using an investigational product within 30 days of randomization.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ven100
Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Reduction in the number of days of antibiotic associated diarrhea during the treatment period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Ning Huang, Ph.D., Ventria Bioscience
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Anticipated)
September 1, 2013
Study Completion (Anticipated)
March 1, 2014
Study Registration Dates
First Submitted
June 21, 2011
First Submitted That Met QC Criteria
June 23, 2011
First Posted (Estimate)
June 27, 2011
Study Record Updates
Last Update Posted (Estimate)
June 27, 2011
Last Update Submitted That Met QC Criteria
June 23, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VB-Ven100-2011-01
- R44AG037211 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diarrhea
-
Aboca Spa Societa' AgricolaUnknownDiarrhea | Diarrhea, Infantile | Chronic Diarrhea | Acute Diarrhea
-
Napo Pharmaceuticals, Inc.Active, not recruitingAdult Solid Tumor | Cancer Therapy-Related Diarrhea | Chemotherapy-related Diarrhea | Prophylaxis of Diarrhea | Symptomatic Relief of Diarrhea | Targeted Therapy-related DiarrheaUnited States, Taiwan, Georgia, Serbia, Argentina
-
South Shore HospitalWithdrawnAntibiotic Associated Diarrhea | Clostridium Difficile Associated Diarrhea
-
Hospital San BartolomeInstituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo...Unknown
-
Cosmo Technologies LtdBausch Health Americas, Inc.CompletedTraveler's DiarrheaGuatemala, Mexico
-
Sana'a UniversityCompleted
-
PATHUniversity of Maryland; Center for Vaccine Development - MaliCompleted
-
Johns Hopkins Bloomberg School of Public HealthNaval Medical Research CenterCompletedTravelers' DiarrheaUnited States
-
Intercell USA, Inc.CompletedTraveler's DiarrheaUnited States
-
Augusta UniversityNRS Medical College, Kolkata, West Bengal, India; School of Tropical Medicine...Terminated
Clinical Trials on Lactoferrin
-
Sunnybrook Health Sciences CentreNational Health and Medical Research Council, Australia; Canadian Institutes...Active, not recruitingMorbidity;Newborn | Preterm Infant | Very Low Birth Weight InfantCanada
-
Inner Mongolia Yili Industrial Group Co., LtdCompletedCommon Cold | Human Influenza | ImmunizationChina
-
Midwest Center for Metabolic and Cardiovascular...HelainaCompletedImmune HealthUnited States
-
Ain Shams UniversityCompletedNeonatal Sepsis
-
Universidad Peruana Cayetano HerediaCompleted
-
Centre Hospitalier de ValenceCompletedMetallic TasteFrance
-
Cairo UniversityUnknown
-
University of VirginiaThe Gerber FoundationUnknownTolerance | Safety Issues | Very Low Birth Weight Infant
-
Ankara UniversityCompletedVery Low Birth Weight Infants | Necrotising Enterocolitis | Late Onset Neonatal SepsisTurkey